Let me highlight a couple of examples. One is in the area of genomics. Modern medical research, now that we've mapped the genome, is based on looking at those genes, looking at the mechanisms they trigger in terms of the proteins they create and how those proteins interact with the body. But one interesting thing is that research tends to clump around a very small number of genes, because it tends to be incremental.
What's going on in Toronto with the Structural Genomics Consortium is an attempt to bring companies together in an open innovation framework to go into uncharted territory to pioneer those others areas of the genome. This is the kind of thing that, when it identifies promising areas, can open up entirely new avenues of medicine.